ExoNeuglia
Latest round
- Angel
Last raised
- Dec 2022
Total raised
- Undisclosed
Investors
- 1
About ExoNeuglia
Based in Suzhou, China, and founded in 2022, ExoNeuglia is a biotechnology company dedicated to the development of speciality neurological-related stem cell drugs. The founder and CEO of the company, Ying Guo, graduated from the University of Barcelona and has been engaged in the research of neural demyelinating disease drugs and stem cell therapy for 11 years. Co-founder Wenbin Deng is the dean of Shenzhen School of Pharmacy, Sun Yat-sen University. The company mainly provides cell and exosome therapy services for neurological diseases. It uses cell reprogramming and induced differentiation technology to develop a technology platform for OPC (Oligodendrocyte Precursor Cells) to treat neurological diseases. ExoNeuglia also focuses on iPSC (induced pluripotent stem cells) cell therapy for neural demyelinating diseases and is dedicated to the development of speciality neurological-related stem cell drugs. The drug is suitable for patients with myelin loss in the nervous system and diseases such as spinal cord injury, multiple sclerosis, and neuromyelitis optical. The company generates revenue by developing specialized neural-related stem cell drugs and providing cell and exosome treatment services for neurological diseases.
Who invested in ExoNeuglia
1 investor across 1 round
See all investors in ExoNeuglia
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Dec 8, 2022
Amount
Undisclosed
Investors
Questions about ExoNeuglia
Who invested in ExoNeuglia?
ExoNeuglia has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ExoNeuglia raised?
ExoNeuglia has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did ExoNeuglia last raise money?
ExoNeuglia's most recent round on record is a Angel, in Dec 2022.
What does ExoNeuglia do?
Based in Suzhou, China, and founded in 2022, ExoNeuglia is a biotechnology company dedicated to the development of speciality neurological-related stem cell drugs.
Where is ExoNeuglia headquartered?
ExoNeuglia is headquartered in Suzhou, China.
Which VCs invest in companies like ExoNeuglia?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at ExoNeuglia's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like ExoNeuglia? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.